← The Wire
DNTHNasdaq
Dianthus Therapeutics, Inc. /DE/
Pharmaceutical Preparations · DE · CIK 1690585
Developing best-in-class therapies for severe autoimmune diseases using novel antibody and fusion protein candidates
⚡ Elevated coverage
$4.49B
Market cap
$95.68
Last close
+0.3%
1D
+9.5%
5D
1.4M
Volume
Price · last 39 sessions+7.1%
May 4L $76.42 · H $95.68Jun 29
182
Total filings
Jun 12, 2026
Last filing
12/31
Fiscal year end
8-KCompany UpdateJun 12, 20268-KShareholder VoteMay 22, 202610-Q10-QMay 5, 20268-KResults of OperationsMay 5, 2026DEFA14ADEFA14AApr 9, 2026DEF 14ADEF 14AApr 9, 20268-KCompany UpdateMar 26, 20268-KMaterial AgreementMar 12, 2026424B5424B5Mar 11, 2026424B5424B5Mar 9, 202610-K10-KMar 9, 20268-KResults of Operations · Reg FD DisclosureMar 9, 20268-KResults of Operations · Reg FD DisclosureJan 12, 202610-Q10-QNov 5, 20258-KResults of OperationsNov 5, 20258-KCompany UpdateNov 3, 20258-KMaterial Agreement · Results of OperationsOct 16, 20258-KMaterial AgreementSep 11, 2025424B5424B5Sep 11, 2025424B5424B5Sep 8, 20258-KReg FD Disclosure · Company UpdateSep 8, 202510-Q10-QAug 7, 20258-KResults of OperationsAug 7, 20258-KExecutive Change · Shareholder VoteMay 22, 202510-Q10-QMay 12, 20258-KResults of OperationsMay 12, 2025DEFA14ADEFA14AApr 10, 2025DEF 14ADEF 14AApr 10, 202510-K10-KMar 11, 20258-KResults of OperationsMar 11, 20258-KExecutive ChangeMar 5, 20258-KCompany UpdateDec 12, 2024SC 13GSC 13GNov 22, 2024SC 13GSC 13GNov 8, 202410-Q10-QNov 7, 20248-KResults of OperationsNov 7, 2024SC 13GSC 13GOct 24, 2024424B5424B5Oct 11, 2024SC 13GSC 13GOct 11, 20248-KExecutive ChangeSep 16, 202410-Q10-QAug 8, 20248-KResults of OperationsAug 8, 20248-KReg FD DisclosureJun 6, 20248-KExecutive Change · Shareholder VoteMay 28, 202410-Q10-QMay 9, 20248-KResults of OperationsMay 9, 2024DEFA14ADEFA14AApr 11, 2024DEF 14ADEF 14AApr 11, 2024S-1/AS-1/AMar 21, 202410-K10-KMar 21, 20248-KResults of OperationsMar 21, 2024S-1/AS-1/AFeb 7, 2024SC 13GSC 13GFeb 2, 2024SC 13GSC 13GFeb 2, 2024SC 13DSC 13DJan 31, 20248-KMaterial Agreement · Equity IssuanceJan 22, 20248-KResults of Operations · Reg FD DisclosureJan 8, 2024S-1/AS-1/ADec 21, 20238-KCompany UpdateDec 21, 2023SC 13GSC 13GNov 13, 202310-Q10-QNov 9, 20238-KResults of OperationsNov 9, 20238-KAuditor ChangeOct 25, 2023SC 13DSC 13DSep 21, 2023SC 13DSC 13DSep 21, 2023SC 13GSC 13GSep 21, 2023SC 13GSC 13GSep 21, 20238-K/AExecutive Change · Results of OperationsSep 21, 20238-KAuditor Change · Change of ControlSep 12, 20238-KShareholder Vote · Company UpdateSep 8, 2023425425Aug 31, 202310-Q10-QAug 3, 2023425425May 19, 20238-KExecutive ChangeMay 19, 2023SC 13GSC 13GMay 15, 202310-Q10-QMay 15, 2023S-4S-4May 15, 2023425425May 3, 20238-KChange of Control · Executive ChangeMay 3, 202310-K/A10-K/AMay 1, 2023
Insider Activity
In the 90 days to Mar 24, 2026: 4 sold $18.5M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 24, 2026 | Soteropoulos PaulaDirector | Sell | 27,594 | $78.05 | $2.2M |
| Mar 12, 2026 | Garcia MarinoCEO AND PRESIDENT | Sell | 65,517 | $81.74 | $5.4M |
| Mar 12, 2026 | Garcia MarinoCEO AND PRESIDENT | Sell | 43,505 | $80.69 | $3.5M |
| Mar 12, 2026 | Randhawa SimratEVP, Head of R&D | Sell | 33,830 | $81.48 | $2.8M |
| Mar 12, 2026 | Carr EdwardCHIEF ACCOUNTING OFFICER | Sell | 23,465 | $81.75 | $1.9M |
| Mar 12, 2026 | Carr EdwardCHIEF ACCOUNTING OFFICER | Sell | 15,852 | $80.71 | $1.3M |
| Mar 12, 2026 | Garcia MarinoCEO AND PRESIDENT | Sell | 12,796 | $82.60 | $1.1M |
| Mar 12, 2026 | Carr EdwardCHIEF ACCOUNTING OFFICER | Sell | 3,865 | $82.66 | $319K |
| Mar 12, 2026 | Garcia MarinoCEO AND PRESIDENT | Sell | 900 | $85.53 | $77K |
| Mar 12, 2026 | Carr EdwardCHIEF ACCOUNTING OFFICER | Sell | 300 | $85.53 | $26K |
| Mar 12, 2026 | Carr EdwardCHIEF ACCOUNTING OFFICER | Sell | 200 | $83.38 | $17K |
| Mar 12, 2026 | Garcia MarinoCEO AND PRESIDENT | Sell | 200 | $83.38 | $17K |
| Dec 4, 2025 | Savitz RyanCFO & CBO | Sell | 20,000 | $45.18 | $904K |
| Nov 14, 2025 | Randhawa SimratEVP, Head of R&D | Sell | 109,031 | $38.14 | $4.2M |
| Nov 13, 2025 | Randhawa SimratEVP, Head of R&D | Sell | 42,765 | $37.04 | $1.6M |
| Nov 13, 2025 | Randhawa SimratEVP, Head of R&D | Sell | 26,166 | $35.80 | $937K |
| Nov 13, 2025 | Randhawa SimratEVP, Head of R&D | Sell | 18,576 | $37.72 | $701K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
In the News
⚡ Elevated coverageCoverage (30d): 1 reputable article · skews – neutral.
Reputable outlets only (Reuters, WSJ, CNBC, Barron's, and peers). More on Google News ↗
Similar companies
Comparable business profile · signals at a glance